IL6 and non-small cell lung carcinoma: The researchers employed a syngeneic genetically engineered mouse model (GEMM) of EGFR-mutant NSCLC to explore the impact of IL-6 on the TME and evaluate the combined efficacy of IL-6 inhibition and anti-PD-1 therapy.